|
|
 |
|
Management Biographies |
|
|
 |
|
|
PETER KUIPER
Group Vice President, Operations - The Netherlands
Schering-Plough Corporation
Oss, The Netherlands
Peter Kuiper, is group vice president, Operations, the Netherlands, for Schering-Plough Corporation.
Kuiper was named to his current position at Schering-Plough in October 2007. He is responsible for Organon manufacturing and has site responsibilities for facilities and administrative services in The Netherlands. He is a member of the Global Supply Chain leadership team.
Before joining Schering-Plough, Kuiper worked for Organon for more than 20 years. He most recently was executive vice president, Global Manufacturing, but also served in the company's Strategy and Global Marketing areas, as well as was the general manager of the company's country operations in Egypt and Canada. Kuiper graduated with an MSc. in pharmacy from Leiden University in 1986, and he earned an M.B.A. degree from Erasmus University in 1987.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
